GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » E10

TG Therapeutics (FRA:NKB2) E10 : €-1.80 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

TG Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was €0.018. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.80 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 58.80% per year. During the past 5 years, the average E10 Growth Rate was 52.00% per year. During the past 10 years, the average E10 Growth Rate was 44.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of TG Therapeutics was 63.10% per year. The lowest was 20.40% per year. And the median was 37.80% per year.

As of today (2024-12-15), TG Therapeutics's current stock price is €29.18. TG Therapeutics's E10 for the quarter that ended in Sep. 2024 was €-1.80. TG Therapeutics's Shiller PE Ratio of today is .


TG Therapeutics E10 Historical Data

The historical data trend for TG Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics E10 Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.13 -23.93 -1.91 -1.85 -1.93

TG Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.98 -1.93 -1.97 -1.92 -1.80

Competitive Comparison of TG Therapeutics's E10

For the Biotechnology subindustry, TG Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Shiller PE Ratio falls into.



TG Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.018/133.0289*133.0289
=0.018

Current CPI (Sep. 2024) = 133.0289.

TG Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.389 99.070 -0.522
201503 -0.323 99.621 -0.431
201506 -0.339 100.684 -0.448
201509 -0.249 100.392 -0.330
201512 -0.340 99.792 -0.453
201603 -0.251 100.470 -0.332
201606 -0.294 101.688 -0.385
201609 -0.445 101.861 -0.581
201612 -0.455 101.863 -0.594
201703 -0.486 102.862 -0.629
201706 -0.401 103.349 -0.516
201709 -0.403 104.136 -0.515
201712 -0.389 104.011 -0.498
201803 -0.478 105.290 -0.604
201806 -0.505 106.317 -0.632
201809 -0.369 106.507 -0.461
201812 -0.607 105.998 -0.762
201903 -0.381 107.251 -0.473
201906 -0.372 108.070 -0.458
201909 -0.627 108.329 -0.770
201912 -0.396 108.420 -0.486
202003 -0.439 108.902 -0.536
202006 -0.417 108.767 -0.510
202009 -0.620 109.815 -0.751
202012 -0.584 109.897 -0.707
202103 -0.580 111.754 -0.690
202106 -0.490 114.631 -0.569
202109 -0.553 115.734 -0.636
202112 -0.620 117.630 -0.701
202203 -0.463 121.301 -0.508
202206 -0.284 125.017 -0.302
202209 -0.263 125.227 -0.279
202212 -0.368 125.222 -0.391
202303 -0.262 127.348 -0.274
202306 -0.314 128.729 -0.324
202309 0.684 129.860 0.701
202312 -0.092 129.419 -0.095
202403 -0.064 131.776 -0.065
202406 0.037 132.554 0.037
202409 0.018 133.029 0.018

Add all the adjusted EPS together and divide 10 will get our e10.


TG Therapeutics  (FRA:NKB2) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


TG Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


TG Therapeutics Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics Headlines

No Headlines